2012). Furthermore, ETAR antagonists are the first‐line treatment option for pulmonary arterial hypertension, and interestingly, are currently being studied for the treatment of diabetic nephropathy (Reichetzeder et al. 2014). The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.